Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Measurement of protein using bicinchoninic acid

1985 • 17,516 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Nonparametric Estimation from Incomplete Observations

1958 • 7,673 citations

ras oncogenes in human cancer: a review.

1989 • 5,116 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

2001 • 883 citations

Blocking Oncogenic Ras Signaling for Cancer Therapy

2001 • 837 citations

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

1992 • 542 citations

Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

1999 • 538 citations

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

2001 • 463 citations

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

2001 • 458 citations

A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

1995 • 393 citations

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules

2000 • 321 citations

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

2000 • 300 citations

Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer

2000 • 275 citations

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

2000 • 247 citations

The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis

2000 • 244 citations

Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.

2002 • 227 citations

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho

1998 • 214 citations

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1998 • 212 citations

Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.

1999 • 210 citations

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I

1997 • 203 citations

Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer

2003 • 200 citations

Isoprenylation of a protein kinase. Requirement of farnesylation/alpha-carboxyl methylation for full enzymatic activity of rhodopsin kinase.

1992 • 196 citations

The gamma subunit of transducin is farnesylated.

1990 • 187 citations

AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon.

2001 • 144 citations

Confidence Intervals for a Binomial Parameter Based on Multistage Tests

1987 • 141 citations

Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer

2002 • 132 citations

Comparison of potential markers of farnesyltransferase inhibition.

2000 • 121 citations

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

2000 • 115 citations

Current status of clinical trials of farnesyltransferase inhibitors

2001 • 114 citations

Farnesyl Protein Transferase Inhibitors and Other Therapies Targeting the Ras Signal Transduction Pathway

1999 • 105 citations

Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells

1997 • 61 citations

Combination studies with the farnesyltransferase inhibitor R115777 and chemotherapy agents

2001 • 7 citations

Oncogenes and cell proliferation Web alert

1998 • 4 citations